Argent Capital Management LLC Purchases New Holdings in Pfizer Inc. $PFE

Key Points

• Argent Capital Management acquired 285,009 Pfizer shares during the third quarter, valued at approximately $8.13 million. Institutional investors collectively own 68.36% of Pfizer’s stock.
• Pfizer recently reported quarterly EPS of $0.77, beating the $0.68 consensus estimate, while revenue rose 2.6% year over year to $15.03 billion. Management issued full-year 2026 EPS guidance of $2.80–$3.00.
• Shares traded near $27.38, while analysts maintain a consensus Hold rating with an average price target of $28.39, reflecting limited near-term upside amid recovery and pipeline-execution risks.

Argent Capital Management LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 285,009 shares of the biopharmaceutical company's stock, valued at approximately $8,128,000.

Other institutional investors have also made changes to their positions in the company. Angeles Wealth Management LLC boosted its stake in shares of Pfizer by 2.2% during the 2nd quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company's stock worth $410,000 after buying an additional 358 shares during the last quarter. Manchester Financial Inc. increased its position in shares of Pfizer by 2.9% in the second quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company's stock valued at $317,000 after acquiring an additional 365 shares during the last quarter. Vermillion Wealth Management Inc. increased its position in shares of Pfizer by 19.4% in the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company's stock valued at $66,000 after acquiring an additional 382 shares during the last quarter. Eagle Capital Management LLC raised its holdings in Pfizer by 0.3% during the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company's stock worth $3,554,000 after acquiring an additional 390 shares in the last quarter. Finally, Delta Financial Advisors LLC boosted its position in Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company's stock valued at $709,000 after purchasing an additional 398 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s potential turnaround is attracting attention after a reported 10 consecutive earnings beats and a fading COVID-related revenue decline. Investors are watching for a pipeline deal that could give Pfizer an entry into the obesity-drug market and potentially support an estimated 20% upside. Pfizer’s Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside
• Positive Sentiment: Analysts and dividend-focused investors continue to view Pfizer’s roughly 6% yield as attractive, particularly because management remains committed to the dividend and is repositioning the business ahead of major patent expirations. The strategy could produce stronger growth beginning in 2029. Here’s Exactly Why I’m Not Afraid of Pfizer’s 6% Dividend Yield
• Neutral Sentiment: A comparative review of Pfizer and healthcare rivals highlights its diversified business and established track record, but also shows that investors must weigh income potential against slower growth and pipeline execution risk. Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
• Neutral Sentiment: Leerink Partners maintained a Hold view on PFE, signaling that the stock’s valuation and recovery prospects appear reasonably balanced rather than presenting a clear near-term catalyst. Pfizer Receives a Hold from Leerink Partners
• Negative Sentiment: Vaxcyte’s lead vaccine candidate produced strong trial results and sent its stock sharply higher, highlighting a potential challenge to Pfizer and Merck in a vaccine market estimated at $3 billion to $6 billion. Vaxcyte Stock Spikes 57% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck

Pfizer Stock Performance

PFE traded down $0.42 during trading hours on Monday, reaching $27.38. The company's stock had a trading volume of 13,252,178 shares, compared to its average volume of 40,565,719. The company's 50-day moving average is $27.41 and its 200-day moving average is $26.48. Pfizer Inc. has a 52 week low of $23.62 and a 52 week high of $29.21. The firm has a market cap of $156.03 billion, a PE ratio of 36.02, a price-to-earnings-growth ratio of 1.87 and a beta of 0.32. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.98 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $27.00 price target on shares of Pfizer in a research report on Monday, July 6th. Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Sunday, September 13th. Guggenheim cut their price target on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a research note on Friday, August 7th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $28.39.

About Pfizer

Pfizer Inc NYSE: PFE is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company's portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.